Triglyceride Glucose Index Predicts Risk of Adverse Cardio-metabolic and Mortality Outcomes Among Chinese Adults: A Territory-Wide Longitudinal Study

Background: The triglyceride glucose (TyG) index has been proposed to be a surrogate of insulin resistance. In the study, we aimed to examine the relationship between TyG index and the risk of new onset DM and secondary outcomes included atrial fibrillation (AF), heart failure (HF), acute myocardial infarction (AMI), ventricular tachycardia/fibrillation (VTF), cardiovascular mortality (CAD) and all-cause mortality. Methods: The retrospective observational study analyzed patients recruited from 1st January 2000 to 31st December 2003 and followed up until 31st December 2019. Demographics, past comorbidities, medications and laboratory tests were extracted. At baseline and follow-up, DM was defined as 1) any occasion Hb1Ac [≥]14 g/dL, 2) fasting glucose[≥]7 mmol/L on two occasions, or 3) with DM diagnosis. We excluded 1) patients with prior DM or with the use of antidiabetic medications; 2) patients with prior AMI/HF/AF or with the use of diuretic/beta blockers for HF were excluded. Univariate analysis and multivariate Cox analysis with adjustments on demographics, past comorbidities and medications were conducted to identify the significant risk predictors of primary and secondary outcomes. Optimal cutoffs of TyG index for the primary and secondary outcomes were found with maximally selected rank statistics approach. Result: Lager TyG index is significantly associated with new onset DM (HR: 1.51, 95% CI: [1.47, 1.55], P vlaue<0.0001), new onset HF (HR: 1.27, 95% CI: [1.2, 1.34], P vlaue<0.0001), new onset AF (HR: 2.36, 95% CI: [2.26, 2.46], P vlaue<0.0001), new onset AMI (HR: 1.51, 95% CI: [1.42, 1.6], P vlaue<0.0001), new onset VTF (HR: 1.22, 95% CI: [1.13, 1.31], P vlaue<0.0001), new onset CAD (HR: 1.56, 95% CI: [1.45, 1.69], P value<0.0001) and all-cause mortality (HR: 1.21, 95% CI: [1.18, 1.25], P vlaue<0.0001). TyG index and its 3rd tertile remained significant after being adjusted with significant demographics, past comorbidities and medicactions in multivariate cox models (HR>1, P value<0.05). Optimal cut-off values of baseline TyG index and adjusted multivariate restricted cubic spline models further uncovered detailed associations of larger baseline TyG index with the primary and secondary outcome. Conclusion: Higher TyG index remained significantly associated with the elevated risk of new onset DM, AF, HF, AMI, VTF, CAD and all-cause mortality after adjustments on demographics, past comorbidities, and medications.


Introduction
The triglyceride glucose (TyG) index has been proposed to be a surrogate of insulin resistance.
It has been shown to predict adverse cardiovascular events in patients with diabetes alone, or with acute coronary syndrome (1), poor prognosis in ischaemic stroke patients (2) and incident diabetes in the general population (3). In the study, we aimed to examine the relationship between TyG index and new onset DM, atrial fibrillation (AF), heart failure (HF), acute myocardial infarction (AMI), ventricular tachycardia/fibrillation (VTF), cardiovascular mortality (CAD) and all-cause mortality.

Study Population
The crude inclusion criteria were as follows: 29944 patients with complete triglyceride and fast glucose tests were recruited from January 1 st , 2000 to December 31 st , 2003 and were followed up until Dec 31 st , 2019 (Figure 1). I n total 5595 patients being excluded with the criteria were as follows: 1) with baseline DM diagnosis (N=1769); 2) With any prior HbA1c occasion ≥ The primary outcome was new onset DM and the secondary outcomes included new onset AF/HF/AMI/VTF/CAD and all-cause mortality. The endpoint date of interest for all eligible patients was event presentation date, mortality, or study end (December 31, 2019). There are no records with follow-up loss. Descriptive statistics were used to summarize patients' characteristics of the primary outcome and secondary outcomes. Continuous variables were presented as median (95% confidence interval [CI] or interquartile range [IQR]) and categorical variables were presented as count (%). The Mann-Whitney U test was used to compare two continuous variables. The Kruskal-Wallis test was used to determine whether more than two continuous variables have a different distribution. The χ 2 test with Yates' correction was used for 2×2 contingency data. The study cohort was compared according to the tertile subgroups of TyG index ( Table 1) and those with/without event presentation

(Supplementary Tables 2-4).
Univariate Cox hazard proportional analysis models were used to identify the significant risk predictors of primary and secondary outcomes. Hazard ratios (HRs) with corresponding 95% CIs and P values were reported accordingly. Kaplan-Meier curves were plotted against the time-to-event for primary and secondary outcomes stratified by deciles of TyG index (Figure 2). Adjusted cubic spline models of the associations between TyG index and the risk of primary and secondary outcomes were presented (Figure 3). Hazard ratios (HRs) of primary and secondary outcomes according to tertiles of TyG index were summarized ( Table 4). Optimal cut-offs of baseline TyG index for primary and secondary outcomes were derived with maximal survival rank statistics approach after adjusting for significant demographics, past comorbidities, and medications with multivariate Cox model, and compared with 1 st tertile subgroup as reference ( Table 5). Adjusted cubic spline model of the associations between TyG index and risk of new-onset DM and all-cause . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021. ; mortality were presented (Figure 4). All significance tests were two-tailed and considered statistically significant if P values were 0.05. Data analyses were performed using RStudio software (Version: 1.1.456) and Python (Version: 3.6).

Clinical and Biochemical Characteristics
The present cohort consists of 24349 patients (40.2% males, median age of initial triglyceride test: 62.5 years old, IQR: 51. 3-71.4, max: 100.97  The crude incidence rates were 33.11% (N=8062), 33.53% (N=8166) and 33.35% (N=8121) for baseline TyG index in the 1st, 2nd, and 3rd tertiles, respectively, as shown in Table 1 for the baseline characteristics according to the tertile subgroups of baseline TyG index. There exist significant differences among the three tertiles of TyG index in incidence rates of all-cause mortality (32.69% v.s. 37.68% v.s. 41.74%, P value<0.0001), CAD (3.15% v.s. 4.38% v.s. 6.16%, P . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Patients in the 3 rd tertile subgroup had significantly lower levels of mean corpuscular volume, mean corpuscular haemoglobin, platelet, reticulocyte, red cell count, hematocrit, urate, albumin, sodium, urea, protein, creatinine, bilirubin and high-density lipoprotein, while had higher levels of . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 5, 2021. ; lymphocyte, monocyte, neutrophil, white cell count, ALP, aspartate transaminase, ALT, triglyceride, low-density lipoprotein, cholesterol, HbA1c and fast glucose (P value<0.05).
In addition, the baseline characteristics of patients with/without event presentation of new onset DM/AF/HF/AMI/VTF/CAD and all-cause mortality were presented in Supplementary Tables 2-4.
Patients in the third tertile had a significant larger value of TyG index (median: 6.7, max: 7.03 v.s. median: 7.31,max: 7.63 v.s. median: 8.04,max: 11.61,P value<0.0001). Kaplan-Meier survival curves of the primary and secondary outcomes stratified by deciles of baseline TyG index were presented in Figure 2.

Significant unirivate risk factors of primary and secondary outcomes
Cox-proportional hazard model analysis identified the significant risk factors of primary and secondary outcomes as shown in Table 2 and Table 3. Important predictors of new onset DM include male gender, older patient age, larger Charlson score, comorbidities of liver diseases, IHD, COPD, and PVD (HR>1, P value<0.05); higher levels of mean corpuscular volume, monocyte, neutrophil, white cell count, mean corpuscular haemoglobin, platelet, reticulocyte, hematocrit, potassium, urea, creatinine, alkaline phosphatase, aspartate transaminase, alanine transaminase, bilirubin, triglyceride, HbA1c, fast glucose (HR>1, P value<0.05), and lower levels of lymphocyte, albumin, sodium, protein, low-density lipoprotein, high-density lipoprotein, and cholesterol (HR<1, P value<0.05). Lager TyG index is significantly associated with new onset DM (HR: 1.51, 95% CI: [1.47, 1.55], P vlaue<0.0001). Significances of the stratified decciles and tertiles of TyG index with new onset DM were also presented in Table 2. Medication prescriptions of all the mentioned drugs were associated with new onset DM (HR>1, P value<0.05).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021. ; Significant risk predictors of new onset HF include male gender, older patient age, larger Charlson score, comorbidities of hypertension, IHD, COPD, PVD, TIA/Ischemic stroke and cancer (HR>1, P value<0.05); higher levels of mean corpuscular volume, monocyte, neutrophil, white cell count, mean corpuscular haemoglobin, platelet, urea, creatinine, alkaline phosphatase, HbA1c, fast glucose (HR>1, P value<0.05), and lower levels of lymphocyte, red cell count, albumin, sodium, protein, alanine transaminase, high-density lipoprotein, and cholesterol (HR<1, P value<0.05). Lager TyG index is significantly associated with new onset HF (HR: 1.27, 95% CI: [1.2, 1.34], P vlaue<0.0001). Significances of the stratified decciles and tertiles of TyG index with new onset DM were also presented. Medication prescriptions of all the mentioned drugs were associated with new onset HF (HR>1, P value<0.05).
Significances of the stratified decciles and tertiles of TyG index with new onset AF were also presented. Medication prescriptions of ACEI, ARB, calcium channel blockers, beta blockers, nitrates, antihypertensive drugs, diuretics for hypertension, anticoagulants and antiplatelets were associated with new onset AF (HR>1, P value<0.05).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021. ; Significant univariate risk predictors of new onset AMI included male gender, older baseline age, larger Charlson score, past comorbidities of hypertension, IHD, COPD, gastrointestinal diseases, PVD, TIA/Ischemic stroke (HR>1, P value<0.05); higher levels of mean corpuscular volume, monocyte, neutrophil, white cell count, mean corpuscular haemoglobin, platelet, reticulocyte, urea, creatinine, alkaline phosphatase, HbA1c, fast glucose (HR>1, P value<0.05), and lower levels of lymphocyte, platelet, red cell count, sodium, protein and high-density lipoprotein (HR<1, P value<0.05). Lager TyG index is significantly associated with new onset AMI (HR: 1.51, 95% CI: [1.42, 1.6], P vlaue<0.0001). Significances of the stratified decciles and tertiles of TyG index with new onset AMI were also presented. Medication prescriptions of all the mentioned drugs were associated with new onset AMI (HR>1, P value<0.05).

Adjusted associations of baseline TyG index with primary and secondary outcomes
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021. ; With 1 st tertile subgroups of baseline TyG index as a reference, it has been found that the 3 rd tertile subgroup were more likely to developed new onset DM/AF/HF/AMI/VTF and meet the outcomes of CAD and all-cause mortality (HR>1, P value<0.05) ( Table 4), after being adjusted for significant demographics, past comorbidities, and medications in different multivariate Cox analysis models.
The optimal cut-off values of baseline TyG index with primary and secondary outcomes were identified with the maximal survival rank statistics approach ( Table 5). Adjusted multivariate restricted cubic spline models identified the associations between baseline TyG index and HR of primary and secondary outcomes were presented in Figure 3.
It has been further confirmed that TyG index above the optimal cut-offs was associated with elevated adverse risk of both the primary and secondary outcomes. Analyses of the associations between baseline TyG index and primary and secondary outcomes with maximal survival rank statistics approach were presented in Figure 4. Subgroup characteristics of triglyceride cut-offs with new onset DM and all-cause mortality were presented in Supplementary Table 2 and Table 3, respectively. Basic characteristics of TyG index cut-offs with primary and secondary outcomes were compared in Supplementary Tables 5-7.

Discussion
The major findings of the present study are summarized as follows: is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021. ; CAD (HR: 1.56, 95% CI: [1.45, 1.69], P value<0.0001) and all-cause mortality (HR: 1.21, 95% CI: [1.18, 1.25], P vlaue<0.0001); 2). 3 rd tertile subgroup (TyG>7.63) were more likely to developed new onset DM/AF/HF/AMI/VTF and meet the outcomes of CAD and all-cause mortality (HR>1, P value<0.05); 3). TyG index and its 3 rd tertile remained significant after being adjusted with significant demographics, past comorbidities and medicactions in multivariate cox models (HR>1, P value<0.05); 4). Optimal cut-off values of baseline TyG index were identified and subgroups with TyG index larger than the cut-offs were significantly associated with the primary and secondary outcome (HR>1, P value<0.05); 5). Adjusted multivariate restricted cubic spline models further uncovered the detailed associations between baseline TyG index and HRs of primary and secondary outcomes.

Limitations
As in other observational studies, this study is limited by potential under-coding of comorbidities, missing data, and coding errors. Additionally, the duration of the complications and the prescribed treatments were not accounted for, which could affect the interpretation of blood pressure value and variability measurements. In addition, this study is conducted based on a Hong Kong cohort, and it is . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021. ; expected that external validity through comparisons with studies from other countries reporting the association between blood pressure variability and adverse outcomes could be conducted for further confirmation. Finally, all patients were older Chinese people, caution should be made when interpreting our findings in younger individuals and other ethnic populations.

Conclusion
Higher TyG index remained significantly associated with the elevated risk of new onset DM, AF, HF, AMI, VTF, CAD and all-cause mortality after adjustments on demographics, past comorbidities, and medications.

Funding
None.  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021.   is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021.  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021.
Alkaline phosphatase, U/L is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021. 0.0003*** HR: Hazard ratio; CI: confidence interval; DM: diabetes mellitus; HF: heart failure; AF: atrial fibrillation; AMI: acute myocardial infarction; VTF: ventricular tachycardia/fibrillation; IHD: ischemic heart disease; COPD: chronic obstructive pulmonary disease; PVD: peripheral vascular disease; TIA: transient ischemic attack; ACEI: angiotensinogen converting enzyme inhibitor; ARB: angiotensin receptor blocker; TyG: triglyceride-glucose . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 5, 2021.